MEDP
T3Medpace Holdings, Inc.
OverviewMedpace Holdings, Inc. (MEDP) offers clinical research services for drug and medical device development, spanning Phase I to Phase IV. It provides comprehensive
Medpace Holdings, Inc. (MEDP) offers clinical research services for drug and medical device development, spanning Phase I to Phase IV. It provides comprehensive support, including laboratory, project management, and regulatory affairs, primarily to pharmaceutical, biotechnology, and medical device companies. The company focuses on smaller and virtual clients, with its top 10 customers accounting for approximately 37% of its last 12 months revenue.
- What They Do (Plain English & Analogies)
- Medpace is like a specialized partner for pharmaceutical, biotechnology, and medical device companies. Imagine a company that wants to develop a new drug or medical device. Instead of doing all the complex and time-consuming testing themselves, they hire Medpace. Medpace designs and manages the entire process of clinical trials, from the very first tests in humans (Phase I) all the way through to post-market support (Phase IV). They handle everything from setting up the study, managing patient data, ensuring regulatory compliance, and analyzing the results. Essentially, they help bring new medicines and devices to market faster and more efficiently, acting as an outsourced research and development arm.
- Very Brief History
- Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio. Over the years, it has evolved to provide a comprehensive suite of clinical research-based drug and medical device development services, supporting the entire clinical development process across various therapeutic areas globally.
- "Street Stereotype"
- The 'Street stereotype' for companies like Medpace, particularly within the broader MedTech sector, often involves scrutiny over valuation. While Medpace is a profitable contract research organization (CRO), investors may perceive it as having a premium multiple, especially given recent concerns about slowing sequential growth and the declining backlog coverage beyond the next 12 months. There's a focus on whether its growth trajectory can justify its valuation in a market that is increasingly valuing earnings visibility over speculative growth stories.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Medpace's customers are primarily in the pharmaceutical, biotechnology, and medical device industries. They specifically focus on serving virtual and smaller companies. While specific client names are not disclosed due to confidentiality, their customer base consists of numerous small to mid-sized biotech and pharma firms developing new therapies and devices.
- New Customers / Segments They'Re Targeting
- Medpace is not explicitly targeting new customer segments or markets. Instead, the company is focused on expanding its pipeline of opportunities and implementing initiatives to improve its win rate within its existing customer base of virtual and smaller pharmaceutical, biotechnology, and medical device companies. They have made a strategic decision not to pursue large pharmaceutical clients due to the different service delivery models required.
- Supply Chain And Sourcing Geographies
- As a Contract Research Organization (CRO), Medpace's 'supply chain' primarily involves its global network of clinical research professionals, laboratories, and clinical trial sites. The company operates across North America, Europe, and Asia. More specifically, Medpace has a global presence with operations in countries including the US, UK, Germany, France, Italy, Spain, Poland, Czech Republic, Hungary, Romania, Russia, Ukraine, Israel, South Africa, India, China, Japan, South Korea, Taiwan, Australia, Argentina, Brazil, Canada, Mexico, and Peru. Their services are delivered through these global operations, leveraging local expertise and resources for clinical trials.
- Sales Geographies And Expansion Plans
- Medpace currently sells its services geographically across North America, Europe, and Asia. The company also has a presence in Latin America and South Africa. Management has not indicated specific plans to expand sales into new geographies, but rather focuses on expanding its pipeline and improving its win rate within its existing global footprint.
- How Key Themes May Help/Hurt
- The 'High Val MedTech' theme primarily focuses on short opportunities for high-multiple, low-margin, or structurally challenged medtech names. While Medpace is a profitable CRO, it could be indirectly hurt by aspects of this theme. If the market continues to shift away from 'speculative growth stories' and scrutinizes 'premium multiples' without corresponding earnings strength, Medpace's valuation could face pressure, especially given recent concerns about its future growth profile and declining long-term backlog. Additionally, a challenging 'capital cycle' or 'market valuation backdrop' could impact the funding environment for Medpace's biotech clients, potentially leading to more cancellations or slower new business awards. Conversely, if the 'rate environment eases sharply' or there's a 'breakout product performance' in the biotech sector, it could reflate growth multiples and improve the funding landscape for Medpace's clients, thereby benefiting the company.
3 Main Long-Term Bull Details
- Specialized Full-Service Model: Medpace's focus on a comprehensive, internally-driven, full-service model for clinical development is highly valued by smaller and virtual biotech companies, allowing them to outsource complex R&D efficiently.
- Strong Financial Performance: The company has demonstrated robust financial performance, with significant revenue and EBITDA growth, strong cash flow from operating activities, and a healthy cash balance, indicating operational efficiency and financial stability.
- High-Quality Opportunity Flow: Despite fluctuations in RFP volume, Medpace continues to view the quality of opportunity flow as good, suggesting a sustained demand for its specialized services from clients with promising development programs.
3 Main Long-Term Bear Details
- Elevated Cancellation Rates: The company has experienced rising cancellation rates, with backlog cancellations reaching their highest point in over a year in Q1 2026, which negatively impacts net bookings and future revenue visibility.
- Weak Net Bookings and Declining Long-Term Backlog: Net bookings have been below the level seen in prior quarters, and the backlog coverage beyond 12 months has deteriorated for six consecutive quarters, raising concerns about the company's sequential revenue growth profile in the future, particularly for 2027.
- Exposure to Biotech Funding Volatility and M&A Impact: While biotech funding has been stable recently, Medpace's client base of smaller biotechs is inherently sensitive to capital market fluctuations. Additionally, client acquisitions by larger pharma companies often result in Medpace being cut out of future work, posing a continuous risk to its project pipeline.
- Competitors And Differentiation
- Medpace operates in the highly competitive Contract Research Organization (CRO) market. Key competitors include larger, diversified CROs such as IQVIA, Labcorp (Covance), PPD (Thermo Fisher Scientific), Syneos Health, Charles River Laboratories, and ICON plc. Medpace differentiates itself by focusing on a full-service, internally-driven expertise model, which they believe provides value to many virtual and smaller companies. They emphasize driving their own efficient process of clinical development, rather than adopting the more flexible, functional outsourcing models often preferred by very large pharmaceutical companies.
- Recent Performance & What The Market'S Focused On
- In Q1 2026, Medpace reported revenue of $706.6 million, a 26.5% year-over-year increase. Net new business awards were $618.4 million, resulting in a 0.88 net book-to-bill ratio. Ending backlog was approximately $2.9 billion, a 2.9% increase from the prior year, with $1.94 billion projected to convert to revenue in the next 12 months. EBITDA increased by 25.9% to $149.4 million, and net income grew 8.1% to $123.9 million, with diluted EPS at $4.28. The company generated $151.8 million in cash flow from operating activities and held $652.7 million in cash. The market is primarily focused on the elevated cancellation rates, which reached their highest point in over a year, and the resulting sub-1.0 net book-to-bill ratio. Investors are also closely watching the declining backlog coverage beyond the next 12 months and its potential impact on future revenue growth, particularly for 2027. The company's ability to expand its pipeline and improve its win rate to counteract these trends is a key area of market attention.
- Revenue Segments And Estimated Mix
- Oncology — Mix: Significant segment; Source: Q1 2026 earnings transcript; Trend: One of the largest therapeutic areas for cancellations, 'kind of usual anyway'.
- Cardiovascular — Mix: Significant segment; Source: Q1 2026 earnings transcript; Trend: One of the largest therapeutic areas for cancellations, 'kind of usual anyway'.
- Metabolic (including GLP-1 related work) — Mix: Large segment; Source: Q1 2026 earnings transcript; Trend: Historically has the lowest cancellation rate among therapeutic areas. Approximately 50% of obesity work is GLP-1 related.
- Product Brands
- {"brands":[]}
Bull / Bear DetailsMedpace Holdings, Inc. faces significant headwinds as of April 24, 2026, with elevated backlog cancellations and a weak net book-to-bill ratio impacting future
Thesis
Medpace Holdings, Inc. faces significant headwinds as of April 24, 2026, with elevated backlog cancellations and a weak net book-to-bill ratio impacting future growth visibility. While current revenue growth remains strong and management is implementing initiatives to improve win rates, the consistent decline in long-term backlog and acknowledged concerns about 2027 sequential growth reinforce a bearish outlook for this high-valuation MedTech name, aligning with the 'MedTech Short '25' theme.
Bull case
Despite facing headwinds, Medpace reported robust revenue growth of 26.5% year-over-year in Q1 2026, and management reconfirmed its full-year 2026 guidance. This indicates confidence in the company's ability to execute on existing projects and manage near-term challenges, suggesting that current operational strength can partially offset booking volatility.
Medpace is actively implementing initiatives to expand its pipeline of opportunities and improve its win rate. Management believes these strategic efforts will combat higher cancellation rates and drive future gross awards, potentially leading to a rebound in bookings and a more favorable book-to-bill ratio in upcoming quarters.
The quality of Medpace's opportunity flow remains good, with strong initial award notifications and win rates. Furthermore, the metabolic/GLP-1 therapeutic area, a significant growth driver, has historically shown the lowest cancellation rates, suggesting resilience and stability in a key segment of its client base.
Bear case
Medpace experienced its highest backlog cancellations in over a year during Q1 2026, resulting in a net book-to-bill ratio of 0.88. This indicates that new business awards are not keeping pace with revenue recognition, leading to a contraction of the backlog and posing a significant threat to future revenue growth.
The company's backlog coverage beyond 12 months has declined for six consecutive quarters, and management explicitly stated that sequential growth in 2027 is a "real question." This diminishing long-term visibility signals structural challenges in securing new business and converting awards into recognized revenue, raising concerns about sustained growth.
RFP volume was down sequentially and year-over-year in Q1 2026, suggesting potential future weakness in gross awards. Additionally, biopharma M&A activity is generally detrimental to Medpace, as acquired clients often cut them out of future work, creating ongoing competitive pressure and limiting growth opportunities.
Bull / Bear Case
- Bear Case
- Medpace faces significant headwinds, marked by Q1 2026 experiencing the highest backlog cancellations in over a year and a weak net book-to-bill ratio of 0.88. This indicates new business awards are not keeping pace with revenue recognition, leading to a contraction of the backlog. The company's backlog coverage beyond 12 months has declined for six consecutive quarters, and management explicitly stated that sequential growth in 2027 is a "real question," raising concerns about long-term growth visibility. Declining RFP volume and the detrimental impact of biopharma M&A on future work further compound competitive pressures and limit growth opportunities.
- Bull Case
- Medpace demonstrated robust revenue growth of 26.5% year-over-year in Q1 2026, and management reconfirmed its full-year 2026 guidance, signaling confidence in current operational execution despite headwinds. The company is proactively implementing initiatives to expand its opportunity pipeline and improve its win rate, aiming to counter elevated cancellation rates. Management maintains that the quality of opportunity flow remains good, with strong initial award notifications. Furthermore, the metabolic/GLP-1 therapeutic area, a significant growth driver, has historically exhibited the lowest cancellation rates, suggesting a degree of resilience and stability in a key market segment. Continued hiring also indicates management's underlying confidence in future demand.
- More Compelling & Why
- Bear. Despite beating Q1 earnings, the stock significantly underperformed, falling over 20% post-earnings, and analysts have cut price targets. The P/E ratio of approximately 33.29x remains elevated, sitting 48% above the Healthcare sector average of 22.53x, suggesting the market is still pricing in substantial growth that is now explicitly questioned by management. The strongest argument for the bear case is the consistent decline in backlog coverage beyond 12 months and management's acknowledgment that 2027 sequential growth is a 'real question.' My view would flip if Medpace demonstrates a sustained net book-to-bill ratio consistently above 1.0, a clear reversal in the trend of declining long-term backlog, and a more attractive valuation multiple.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Conversion of Pre-Backlog Awards to Bookings | While Medpace reported 'good' initial award notifications and win rates in Q1 2026, there is a significant lag (average 3-5 quarters) and risk of cancellation before these awards convert into recognized bookings (first patient in). Slow or high-cancellation conversion indicates continued demand challenges. | Management commentary on the conversion rate of initial awards into recognized bookings, and any specific metrics provided on pre-backlog cancellations. Watch for any indications of delays or increased attrition in this 'pre-backlog' bucket. | Bearish: Slower-than-expected conversion of prior awards into recognized bookings, or an increase in pre-backlog cancellations, suggesting that the 'good' awards are not translating into future revenue as effectively. | Company earnings calls and transcripts for management commentary. This is largely qualitative information provided by management. | ||
| RFP Volume Trends | A sustained decline in Request for Proposal (RFP) volume, despite management's downplaying, could indicate a weakening pipeline of new opportunities and broader demand softness in the biotech sector, impacting future gross awards and overall growth. | Management commentary on sequential and year-over-year RFP trends. Watch for a continued decline in RFP volume or a negative shift in their qualitative assessment of opportunity flow. | Bearish: Continued sequential and year-over-year decline in RFP volume, or a negative shift in management's qualitative assessment of opportunity quality, signaling potential future weakness in gross awards. | Company earnings calls and transcripts. Industry reports from CRO market intelligence firms might offer broader market RFP trends. | Industry reports from CRO market intelligence firms (e.g., ISR Reports, Clinical Leader) might offer broader market RFP trends. | IQVIA: Overall CRO market RFP activity; EvaluatePharma: Clinical trial pipeline and new study initiations. |
| Backlog Coverage Beyond 12 Months | A declining portion of backlog projected to convert beyond the next 12 months signals reduced long-term revenue visibility and potential for a significant growth slowdown in future years (e.g., 2027). This directly impacts the long-term growth profile and valuation. | The absolute dollar value and percentage of total ending backlog projected to convert *beyond* the next 12 months. This figure has declined for six consecutive quarters. | Bearish: Continued decline in the dollar value or percentage of backlog converting beyond 12 months, especially if it falls below current levels, reinforcing concerns about 2027 sequential growth. | Company earnings presentations (slides often break this out) and 10-Q filings. The next earnings call for Q2 2026 will provide an update. | ||
| Backlog Cancellation Rate | Elevated cancellations directly reduce future revenue from existing projects, impacting growth and profitability. For a short position, increasing cancellations confirm demand weakness and execution risk, validating concerns about the company's ability to maintain its growth profile. | Quarterly backlog cancellation rate as a percentage of beginning backlog. Specifically, watch if the rate remains above or increases from the Q1 2026 level, which was the highest in over a year. | Bearish: Cancellation rate above Q1 2026 levels or sustained high levels, indicating continued pressure on future revenue and potentially confirming a 'structurally challenged' aspect of the short thesis. | Company earnings calls, investor presentations, and 10-Q filings (if detailed enough). The next earnings call for Q2 2026 will provide an update. | ||
| Net Book-to-Bill Ratio | A net book-to-bill ratio below 1.0 indicates that new business awards are not keeping pace with revenue recognized, leading to a shrinking backlog. This is a critical indicator of future revenue trajectory and demand health, directly impacting the company's growth prospects. | The quarterly net book-to-bill ratio. Specifically, monitor if it remains consistently below 1.0, or if it further declines from the Q1 2026 ratio of 0.88. | Bearish: Net book-to-bill ratio consistently below 1.0, especially if it remains at or below 0.88, signaling continued contraction of the backlog and potential future revenue deceleration. | Company earnings press releases, earnings call transcripts, and investor presentations. The next earnings call for Q2 2026 will provide an update. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| Ending Backlog (YoY Growth) | Ending Backlog represents contracted future revenue. Its year-over-year growth rate, particularly the portion beyond 12 months, is a key indicator of the company's long-term health and ability to secure new business amidst rising cancellations. | 2.9% |
| Total Revenue | Total Revenue is a core indicator of company performance and growth. Investors will closely watch if Medpace can maintain its revenue guidance despite current booking headwinds and elevated cancellations. | 26.5% |
| Net Book-to-Bill Ratio | The Net Book-to-Bill Ratio is crucial for future revenue visibility. A ratio below 1.0, as seen in the last quarter, indicates that new business awards are not keeping pace with revenue recognition, raising concerns about long-term growth. | -2.2% |
Key QuestionsWill Medpace's elevated backlog cancellation rates persist or worsen, further pressuring the net book-to-bill ratio below 1.0 and confirming a deceleration in f
Will Medpace's elevated backlog cancellation rates persist or worsen, further pressuring the net book-to-bill ratio below 1.0 and confirming a deceleration in future revenue growth?
- Question 2
Will Medpace's backlog coverage beyond 12 months continue its six-quarter decline, confirming a weakening long-term growth profile and validating concerns about 2027 sequential revenue deceleration?
- Question 3
Despite management's initiatives, will declining RFP volumes and weak gross awards persist, indicating a fundamental challenge in securing new business and further undermining Medpace's growth trajectory?
Earnings Transcript Summary
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Expanding the pipeline of opportunities and improving the win rate: Management is focused on implementing initiatives to expand their pipeline and improve their win rate to combat higher cancellation rates. 2. Maintaining 2026 revenue guidance: Despite headwinds from cancellations and a sub-1 book-to-bill ratio, management reconfirmed their 2026 guidance, expressing confidence in their current modeling. 3. Investing in AI for future benefits: Management believes AI holds value but expects significant investment over the next two years, with net benefits in efficiency anticipated a few years out. | The overall takeaway from the call is one of caution regarding future growth, tempered by management's determined efforts to address current challenges. The tone was mixed, with management acknowledging significant headwinds such as the highest backlog cancellations in over a year and a weak net book-to-bill ratio of 0.88. However, they expressed confidence in maintaining their 2026 revenue guidance and highlighted ongoing initiatives to expand the opportunity pipeline and improve win rates. There's an explicit acknowledgment that sequential growth is a 'real question' for 2027, indicating a more conservative outlook for the longer term if current trends persist. | For the fourth quarter of 2025, Medpace reported an overall revenue increase of 32.0% year-over-year. No specific segment revenue growth figures were provided for the prior quarter. | 1. Cancellations: Analysts repeatedly questioned the dynamics, drivers, therapeutic areas, and Q2 trends of the elevated cancellations. Management responded that cancellations were due to 'random stuff' like product performance and reprioritizations, not macro-related, with oncology and cardiovascular being the largest therapeutic areas. They stated it was too early to assess Q2 cancellation rates. 2. GLP-1/Metabolic concentration and volatility: Analysts inquired about Medpace's exposure to GLP-1 and metabolic studies and whether this concentration was leading to increased volatility or cancellations. Management clarified that metabolic historically has the lowest cancellation rate among therapeutic areas and that GLP-1 work is 'pretty safe' and 'going fine,' despite potential market saturation impacting new opportunities. 3. Backlog decline and future growth profile: Analysts expressed concern over the declining backlog coverage beyond one year and its implications for future revenue growth. Management acknowledged this as an 'area for concern,' stating that sequential growth in 2027 is a 'real question' and that they need either cancellations to abate or gross awards to increase to achieve a desired growth rate. | Medpace reported total revenue of $706.6 million for the first quarter of 2026, representing a year-over-year increase of 26.5% (25.8% on a constant currency basis). No specific revenue segments were reported in the transcript. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Medpace is focused on expanding its pipeline of opportunities and has implemented a number of initiatives to improve its win rate to combat higher cancellation rates. | The market is very competitive, and Medpace aims to improve its win rate, though it's unclear if increased competitiveness is the direct cause of recent trends. | Biopharma M&A is generally not good for Medpace, as acquired clients often cut them out of future work, though ongoing projects usually continue. While biotech funding has remained stable, RFP weakness was observed, but Medpace does not see widespread funding problems or clients merely seeking bids for fundraising purposes. The GLP-1 market, despite becoming saturated and competitive, has not resulted in higher cancellations for Medpace, and metabolic studies historically have the lowest cancellation rate. | Medpace needs cancellations to abate or gross awards to increase to restore a desirable growth rate, as sequential growth is currently a concern. The company anticipates improving bookings over time. Pass-throughs as a percentage of revenue are expected to end the year lower than the first quarter. AI is expected to require significant investment over the next two years, with actual net benefit on efficiency still a few years out. | Regarding | AI (Artificial Intelligence) | We continue to view the quality of opportunity flow as good. Initial award notifications and win rate were strong. We feel very good about the range that we have out there, which is why we reconfirmed guidance. We're still hiring. I don't know how you get any more confident than that. I believe we have very high-quality opportunities, and I haven't seen a deterioration of that. | Quarter 1 of 2026 saw cancellations rise again with backlog cancels reaching their highest point in over a year. Net bookings were below the level of -- seen in Q4, but well above those in Q1 2025 with a net book-to-bill ratio of 0.88. RFPs were down in the quarter sequentially and year-over-year. Acquisitions are not good for us? No, but it happens all the time. Certainly, what we consider a reasonable growth rate is not projected on a sequential basis going forward. | Medpace is continuing to hire, which management views as a signal of confidence. The company has seen improved retention rates, contributing to operating efficiencies. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-04-22 | Medpace's Q1 2026 revenue grew 26.5%, but a weak 0.88 net book-to-bill, driven by record cancellations and soft gross bookings, raised concerns. Management acknowledged risks to future sequential growth despite maintaining 2026 guidance. The market reacted negatively, with the stock dropping over 20%, signaling significant apprehension regarding booking trends and future growth prospects. | Earnings Transcript | Neutral | False | -20.46% (vs SPY: -20.07%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| MEDP_54a92808 | over the next few quarters | 2026-04-01 | 2026-12-31 | Outcome of Medpace's initiatives to expand its pipeline of opportunities and improve its win rate, and the resulting trend in cancellation rates and net new business awards. | High cancellation rates and weak gross bookings have led to a low book-to-bill ratio and raise concerns about future revenue growth. Success in these initiatives is critical to improving backlog and restoring a desired growth profile. | Ticker | 2026-04-22 | earnings_transcript |
| MEDP_295080d7 | end the year lower than what we started this year at | 2026-04-22 | 2026-12-31 | Realization of management's expectation for pass-through revenues to decrease as a percentage of total revenue, driven by the winding down of some metabolic studies. | A decrease in the proportion of pass-through revenues, which typically have lower margins, could positively impact the company's overall EBITDA margin and the quality of its revenue. | Ticker | 2026-04-22 | earnings_transcript |
| MEDP_e1f9490e | a few years out | 2028-01-01 | 2029-12-31 | Medpace achieving net financial benefits from its investments in Artificial Intelligence (AI) initiatives. | While AI is a significant industry trend, management expects that investments in AI will outweigh efficiency gains for at least the next two years, impacting the timeline for any positive financial contribution from AI. | Ticker | 2026-04-22 | earnings_transcript |
| MEDP_f4e43f3e | not in the near term | 2026-07-01 | 2027-04-22 | Medpace appoints a new President to succeed Jesse Geiger, who is departing. | The appointment of a new President is a key leadership transition that could influence strategic direction, operational execution, and investor confidence, despite management's assurance of a strong team. | Ticker | 2026-04-22 | earnings_transcript |